



MITHRA PHARMACEUTICALS TO HOST INVESTOR DAY EVENT ON JUNE 29TH, 2016 IN BRUSSELS

Liège, Belgium 25 May 2016 – Mithra announces that it will host its Investor Day event on June 29th 2016 in Brussels from 8:30 AM to 5:30 PM in the attendance of the CEO François Fornieri, Jean-Michel Foidart as a member of the Scientific Committee and other Mithra executives.

Mithra will provide an update on its strategic plan and present an overview of its operations, R&D developments and outlooks for the upcoming years. The event will include presentations and Q&A with the Executive Team, led by the CEO, François Fornieri.

Program:

8:30 – 9:00	Registration
9:00 – 9:05	Welcome (Jean-Manuel Fontaine)
9:05 – 10:05	The unique potential of Estetrol (Jean-Michel Foidart)
10:05 – 11:05	Company and Financial Update with CEO and CFO
11:05 – 11:45	Q&A panel
11:45 – 13:30	Drink and lunch with management
13:30 – 14:30	Focus on Estetrol based projects (Estetrol-Estelle-Donesta)
14:30 – 14:45	Coffee Break
14:45 – 15:45	Focus on controlled release products and CDMO
15:45 – 16:15	Q&A panel and Wrap up
16:15 – 17:30	Drink

All investors, analysts and members of the financial community interested in attending have to register in advance. For those who are unable to attend in person, Mithra will webcast a live video of the meeting via its website investors.mithra.com.

Event registration and further information by e-mail to investorrelations@mithra.com

Pictures

For pictures of François Fornieri, please click here on the following link:

<http://www.mithra.com/en/logo/>

For more information, please contact:

Press

Julie Dessart

Chief Communication Officer

+32 4 349 28 22

+32 475 86 41 75

press@mithra.com

Investor Relations

François Fornieri, CEO

+32 4 349 28 22

investorrelations@mithra.com

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical entities in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com